Thinly traded nano cap Alpine Immune Sciences (NASDAQ:ALPN) is up 8% premarket, albeit on only 1,008 shares, on the heels of new preclinical data on lead candidate ALPN-101. The results were presented at the Crohn’s & Colitis Congress in Austin, TX.
In a T cell transfer model of chronic inflammatory
bowel disease (IBD), ALPN-101 showed “superior” suppression of
proinflammatory cytokines in vitro compared to single CD28 or
ICOS pathway inhibitors in peripheral blood mononuclear cells from a
colitis patient. It also showed effector memory T cell and cytokine
suppression in mouse models of IBD.
ALPN-101 is a dual CD28/ICOS antagonist also in development for graft-versus-host disease.
https://seekingalpha.com/news/3534340-alpine-immune-sciences-up-8-premarket-on-encouraging-data-on-lead-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.